ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO756

Podocyte Loss and Progression of CKD in Pregnancy

Session Information

Category: Women's Health and Kidney Diseases

  • 2100 Women's Health and Kidney Diseases

Authors

  • Eren, Dilara, King's College London, London, United Kingdom
  • Gill, Carolyn, King's College London, London, United Kingdom
  • Joslin, Jennifer R., King's College London, London, United Kingdom
  • Bramham, Kate, King's College London, London, United Kingdom
  • Smith, Priscilla, King's College London, London, United Kingdom
Background

Chronic kidney disease (CKD) in pregnancy is associated with deterioration in kidney function, but there are no biomarkers to predict or detect progression. Urinary podocyte loss is recognised in progressive glomerular diseases outside of pregnancy and preeclampsia but has not been explored in CKD pregnancy.

Methods

Urine pellets collected in two prospective studies of pregnant women with CKD were analysed for podocyte proteins (Nephrin, Podocalyxin and Podocin) using validated sandwich enzyme-linked immunosorbent assays. Participants included 20 with pregnancy associated progression of CKD (PrCKD), 10 with stable CKD (StCKD), and 10 without CKD (Controls).

Results

Serum creatinine increased in women with PrCKD throughout pregnancy and post-partum. Placental growth factor concentrations were normal in all women, but podocin concentrations in controls were significantly higher in women with PrCKD and StCKD than Controls (see figure 1); there were no differences between women with PrCKD and StCKD. There were no significant differences between groups for Nephrin and Podocalyxin. Demographic data are shown in Figure 2.

Conclusion

Nephrin, Podocin and Podocalyxin can be identified in the urine pellet in pregnancy, with increased podocin concentrations in CKD pregnancy suggesting increased podocyte cell loss, which requires confirmation in a larger prospective cohort.

§ Podocin Concentration Mean (±SD)